Michael S. Conners
New York Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael S. Conners.
Biochemical Pharmacology | 1997
Michal Laniado-Schwartzman; Nader G. Abraham; Michael S. Conners; Michael W. Dunn; Richard D. Levere; Attallah Kappas
Heme oxygenase (HO), by catabolizing heme to bile pigments, down-regulates cellular levels of heme and hemeproteins; certain of the latter, i.e. cytochrome P450s, generate pro-inflammatory products from endogenous substrates. Two HO isozymes, the products of distinct genes, have been described; HO-1 is the inducible one, whereas HO-2 is believed to be constitutively expressed. We studied the inducing effects of several metal compounds [CoCl2, SnCl2, ZnCl2, heme, and cobalt protoporphyrin (CoPP)] on HO-1 mRNA content and enzyme activity in cultures of rabbit corneal epithelial (RCE) cells; these metal compounds are known to induce HO in other tissues. Additionally, we studied HO-1 expression in an experimental model of ocular inflammation produced in rabbit corneas by extended contact lens wear, and the relation of HO expression to the induced inflammatory process. SnCl2 added to RCE cells in vitro produced marked time- and concentration-dependent increases in HO-1 mRNA and HO-1 enzyme activity; CoCl2, ZnCl2, and CoPP were inducers of HO as well, though to a lesser degree than SnCl2. Corneas treated for 6 days with contact lenses impregnated with SnCl2 displayed substantially less corneal inflammation, swelling, and new vessel invasion than did controls; attenuation of ocular inflammation was paralleled by SnCl2-induced increases in HO mRNA and HO activity in corneal epithelial cells from treated eyes. It is suggested that amelioration of the inflammatory response produced by extended contact lens wear is due, in part, to the induction of high levels of HO-1 activity by SnCl2, which results in diminished production of pro-inflammatory mediators generated through heme-dependent metabolic processes. Regulation of HO activity in this manner may have clinical applications.
Biochimica et Biophysica Acta | 1994
Satoru Yamamoto; Motonubu Nishimura; Michael S. Conners; Robert A. Stoltz; John R. Falck; Kamlesh Chauhan; Michal Laniado-Schwartzman
The R and S enantiomers of 12-hydroxyeicosatetraenoic acid (12-HETE) exhibit different biological activities. Although they appear to be produced by different enzymatic pathways, cytochrome P-450 monooxygenase and lipoxygenase, respectively, they display similar metabolism in both corneal epithelium and neutrophils. In corneal epithelial microsomes, both enantiomers are subject to oxidation and keto reduction reactions to form the dihydro metabolite, 12-hydroxy-5,8,14-eicosatrienoic acid (12-HETrE), via a keto intermediate. The apparent Km for the formation of 12-HETrE was 17.9 and 20 microM for 12(R)-HETE and 12(S)-HETE, respectively, and the apparent Vmax of the reaction was 17.4 and 8.2 pmol/mg per min, respectively. Chiral analysis of the dihydro metabolite demonstrated a product enantiospecificity. Arachidonic acid, 12(R)-HETE, 12(S)-HETE and the intermediate of this reaction, 12-oxo-ETrE, were metabolized predominantly to 12(R)-HETrE in a ratio [12(R)-HETrE: 12(S)-HETrE] of 7.3:1, 4.3:1, 1.5:1 and 2.3:1, respectively. 12(R)-HETrE is a potent vasodilator, chemotactic and angiogenic factor whose synthesis is induced in inflamed tissues; 12(S)HETrE is devoid of these properties. 12(R)-HETE, derived from NADPH-dependent cytochrome P-450 monooxygenases, and 12(S)-HETE, derived from 12-lipoxygenase, may both play an important role in regulating the inflammatory response by serving as substrates for the local synthesis of 12(R)-HETrE.
Investigative Ophthalmology & Visual Science | 1995
Michael S. Conners; Robert A. Stoltz; K L Davis; Michael W. Dunn; Nader G. Abraham; Richard D. Levere; Michal Laniado-Schwartzman
Kidney International | 1994
Carolyn M. Macica; Michael S. Conners; Nicholas R. Ferreri
Investigative Ophthalmology & Visual Science | 1997
Michael S. Conners; F Urbano; C Vafeas; Robert A. Stoltz; Michael W. Dunn; Michal Laniado Schwartzman
Investigative Ophthalmology & Visual Science | 1995
Michael S. Conners; Robert A. Stoltz; S C Webb; J Rosenberg; Michael W. Dunn; Nader G. Abraham; Michal Laniado-Schwartzman
Journal of Biological Chemistry | 1994
Michal Laniado-Schwartzman; Yan Lavrovsky; Robert A. Stoltz; Michael S. Conners; John R. Falck; Kamlesh Chauhan; Nader G. Abraham
Investigative Ophthalmology & Visual Science | 1992
K L Davis; Michael S. Conners; Michael W. Dunn; Michal Laniado Schwartzman
Journal of Ocular Pharmacology and Therapeutics | 1994
Robert A. Stoltz; Michael S. Conners; Michael W. Dunn; Michal Laniado Schwartzman
Journal of Ocular Pharmacology and Therapeutics | 1996
Michael S. Conners; Robert A. Stoltz; Michal Laniado Schwartzman